• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.

作者信息

Ahmed Sarah Abdalla, Kloezen Wendy, Fahal Ahmed H, de Hoog G Sybren, van de Sande Wendy W J

机构信息

Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands

Erasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands.

出版信息

Antimicrob Agents Chemother. 2015 Feb;59(2):1373-4. doi: 10.1128/AAC.04487-14. Epub 2014 Dec 8.

DOI:10.1128/AAC.04487-14
PMID:25487799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4335904/
Abstract
摘要

相似文献

1
In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.当前使用的唑类药物与特比萘芬对马杜拉足分支菌的体外相互作用。
Antimicrob Agents Chemother. 2015 Feb;59(2):1373-4. doi: 10.1128/AAC.04487-14. Epub 2014 Dec 8.
2
In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.棘状外瓶霉对泊沙康唑和特比萘芬的体外敏感性。
Antimicrob Agents Chemother. 2011 Apr;55(4):1771-3. doi: 10.1128/AAC.01045-10. Epub 2011 Jan 24.
3
In vitro antifungal activity of isavuconazole against Madurella mycetomatis.体外伊曲康唑抗荚膜组织胞浆菌的活性。
Antimicrob Agents Chemother. 2012 Nov;56(11):6054-6. doi: 10.1128/AAC.01170-12. Epub 2012 Sep 10.
4
Madurella mycetomatis is highly susceptible to ravuconazole.米卡多毛孢菌对拉夫康唑高度敏感。
PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2942. doi: 10.1371/journal.pntd.0002942. eCollection 2014 Jun.
5
Azoles, allylamines and drug metabolism.唑类、烯丙胺类与药物代谢。
Br J Dermatol. 1992 Feb;126 Suppl 39:14-8. doi: 10.1111/j.1365-2133.1992.tb00003.x.
6
Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis.两性霉素B和特比萘芬可延长感染马杜拉足分支菌的大蜡螟幼虫的存活时间，但唑类药物则不能。
Med Mycol. 2018 Jun 1;56(4):469-478. doi: 10.1093/mmy/myx064.
7
Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis.联合使用两种抗真菌药物并不能提高感染马杜拉放线菌的大蜡螟幼虫的存活率。
Trop Med Int Health. 2017 Jun;22(6):696-702. doi: 10.1111/tmi.12871. Epub 2017 May 2.
8
Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.马杜拉足分支菌中的黑色素生物合成及其对伊曲康唑和酮康唑敏感性的影响。
Microbes Infect. 2007 Jul;9(9):1114-23. doi: 10.1016/j.micinf.2007.05.015. Epub 2007 May 18.
9
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.通过改良的美国国立临床实验室标准化委员会（NCCLS）方法和基于活性的2,3-双（2-甲氧基-4-硝基-5-磺基苯基）-5-[(苯胺基)羰基]-2H-氢氧化四唑（XTT）测定法评估马杜拉足分支菌对伊曲康唑和两性霉素B的体外敏感性。
Antimicrob Agents Chemother. 2004 Jul;48(7):2742-6. doi: 10.1128/AAC.48.7.2742-2746.2004.
10
Development and Validation of an Resazurin-Based Susceptibility Assay against .基于刃天青的针对……的药敏试验的开发与验证
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01338-20.

引用本文的文献

1
Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.真（霉）菌病病原体：系统综述为世界卫生组织真菌病原体优先排序提供信息。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae044.
2
The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.马尼格匹克斯与伊曲康唑联合使用具有协同作用，可抑制体外蕈样霉菌的生长，但在体内无效。
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad118.
3
An update on the development of novel antifungal agents for eumycetoma.新型真菌性足菌肿抗真菌药物的研发进展
Front Pharmacol. 2023 May 18;14:1165273. doi: 10.3389/fphar.2023.1165273. eCollection 2023.
4
Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.棘白菌素类药物（伊曲康唑和拉夫康唑）治疗足菌肿（一种最常见的真菌病）的流行病学截断值。
Mycoses. 2022 Dec;65(12):1170-1178. doi: 10.1111/myc.13509. Epub 2022 Aug 25.
5
Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.抑制 DHN- 和 DOPA- 黑色素生物合成途径可提高伊曲康唑治疗蜡状菌感染的金龟子幼虫的疗效。
Med Mycol. 2022 Feb 2;60(2). doi: 10.1093/mmy/myac003.
6
In vitro susceptibility testing for black grain eumycetoma causative agents.体外药敏试验对黑色颗粒外瓶霉病致病因子。
Trans R Soc Trop Med Hyg. 2021 Apr 14;115(4):343-354. doi: 10.1093/trstmh/traa184.
7
Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.引起足菌肿的马杜拉分支菌的医学治疗：挑战与前景。
PLoS Negl Trop Dis. 2020 Aug 27;14(8):e0008307. doi: 10.1371/journal.pntd.0008307. eCollection 2020 Aug.
8
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.马杜拉分枝霉菌是真菌性肿廇的主要病原体，对奥利万星高度敏感。
J Antimicrob Chemother. 2020 Apr 1;75(4):936-941. doi: 10.1093/jac/dkz529.

本文引用的文献

1
Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.临床重要皮肤癣菌对他汀类药物及不同他汀类药物与抗真菌药物组合的敏感性。
Med Mycol. 2014 Feb;52(2):140-8. doi: 10.3109/13693786.2013.828160.
2
In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.棘状外瓶霉对泊沙康唑和特比萘芬的体外敏感性。
Antimicrob Agents Chemother. 2011 Apr;55(4):1771-3. doi: 10.1128/AAC.01045-10. Epub 2011 Jan 24.
3
The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis.伊曲康唑治疗足放线菌属真菌病引起的真菌性足菌肿患者的安全性和疗效。
Trans R Soc Trop Med Hyg. 2011 Mar;105(3):127-32. doi: 10.1016/j.trstmh.2010.11.008. Epub 2011 Jan 17.
4
Clinical efficacy and safety of oral terbinafine in fungal mycetoma.口服特比萘芬治疗真菌性足菌肿的临床疗效与安全性
Int J Dermatol. 2006 Feb;45(2):154-7. doi: 10.1111/j.1365-4632.2004.02392.x.
5
Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.马杜拉足分支菌引起的足菌肿：一种被忽视的感染负担。
Lancet Infect Dis. 2004 Sep;4(9):566-74. doi: 10.1016/S1473-3099(04)01131-4.
6
In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.通过改良的美国国立临床实验室标准化委员会（NCCLS）方法和基于活性的2,3-双（2-甲氧基-4-硝基-5-磺基苯基）-5-[(苯胺基)羰基]-2H-氢氧化四唑（XTT）测定法评估马杜拉足分支菌对伊曲康唑和两性霉素B的体外敏感性。
Antimicrob Agents Chemother. 2004 Jul;48(7):2742-6. doi: 10.1128/AAC.48.7.2742-2746.2004.
7
Mycetoma.
Br J Dermatol. 1994 Nov;131(5):722-3.
8
Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii.
Trans R Soc Trop Med Hyg. 1984;78(3):376-9. doi: 10.1016/0035-9203(84)90126-3.